ArticleCancer cell2013
Tumor dissemination: an EMT affair.
Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed.
- Identification of epithelial, mesenchymal, and platelet-associated circulating tumour cells with translational implications in oral squamous cell carcinoma.Scientific reports · 2026Article
- Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets-A New Perspective?International journal of molecular sciences · 2026Article
- Characterization of Disseminated Tumor Cells (DTCs) in Patients with Triple-Negative Breast Cancer (TNBC).Cells · 2025Article
- Potential biological roles of exosomal non-coding RNAs in breast cancer.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Determination ofPlants (Basel, Switzerland) · 2024Article
- CircXRN2 accelerates colorectal cancer progression through regulating miR-149-5p/MACC1 axis and EMT.Scientific reports · 2024Article
- MLPH regulates EMT in pancreatic adenocarcinoma through the PI3K-AKT signaling pathway.Journal of Cancer · 2024Article
- Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer.Frontiers in oncology · 2024Review
- Linking EMT Status of Circulating Tumor Cells to Clinical Outcomes in Lung Cancer.Cancer management and research · 2024Article
- Fractionation and phytochemical composition of an ethanolic extract ofFrontiers in pharmacology · 2024Article
- Paracrine regulation of neural crest EMT by placodal MMP28.PLoS biology · 2023Article
- Significance of circulating tumor cells in lung cancer: a narrative review.Translational lung cancer research · 2023Review
- E-liquid alters oral epithelial cell function to promote epithelial to mesenchymal transition and invasiveness in preclinical oral squamous cell carcinoma.Scientific reports · 2023Article
- LINC00543 promotes colorectal cancer metastasis by driving EMT and inducing the M2 polarization of tumor associated macrophages.Journal of translational medicine · 2023Article
- Deep learning assisted holography microscopy for in-flow enumeration of tumor cells in blood.RSC advances · 2023Article
- Article
- Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.BMC cancer · 2023Article
- Inhibition of NF-kB/IL-6/JAK2/STAT3 Pathway and Epithelial-Mesenchymal Transition in Breast Cancer Cells by Azilsartan.Molecules (Basel, Switzerland) · 2022Article
- Role of RBMS3 Novel Potential Regulator of the EMT Phenomenon in Physiological and Pathological Processes.International journal of molecular sciences · 2022Review
- A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.Molecular cancer · 2022Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent paper reports that circulating tumor cells (CTCs) from metastatic breast cancer patients exhibit heterogeneous epithelial and mesenchymal phenotypes and that CTCs display higher frequencies of partial or full-blown mesenchymal phenotype than carcinoma cells within primary tumors. Mesenchymal-like CTCs are also elevated in patients who are refractory to therapy.
Identifiers
23518345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.